February 16, 2024Open Access

Supplementary Figure S1 from Clinical Benefit of Avapritinib in KIT-Mutant Gastrointestinal Stromal Tumors: A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 Studies

Key points are not available for this paper at this time.

Supplementary Figure S1. Examples of remarkable tumor regression in patients with KIT-only-mutant GIST during treatment with avapritinib 300 mg QD.

Bookmark

View Full Paper

Cite This Study

Heinrich et al. (Fri,) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Bookmark

View Full Paper